A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
Enrolling by invitation · Phase 2
Conditions studied: Myotonic Dystrophy Type 1 (DM1)
In brief
The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).
Key facts
- Study ID
- NCT06926621
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 44
- Starts
- 2025-04-28
- Expected to finish
- 2029-01-30
- Last updated by the study team
- 2026-08-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- St. Louis Children's Hospital - Neurology — St Louis, Missouri, United States
- Virginia Commonwealth University - Sanger Hall — Richmond, Virginia, United States
- Wesley Research Institute — Auchenflower, Australia
- Neuroscience Clinical Trials Unit, Alfred Brain — Melbourne, Australia
- Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Pulmonology — Leuven, Belgium
- Altasciences Montreal — Montreal, Canada
- Montreal Neurological Institute-Hospital — Montreal, Canada
- University of Ottawa — Ottawa, Canada
- Universite Laval - Neurology — Québec, Canada
- Friedrich Baur Institute — München, Germany
- Maastricht UMC — Maastricht, Netherlands
- Hospital Universitario y Politecnico La Fe - Neurology — Valencia, Spain
- Queen Elizabeth University Hospital - Neurology — Glasgow, United Kingdom
- Leonard Wolfson Experimental Neurology Centre CRF — London, United Kingdom
- Royal Hallamshire Hospital - Neurology — Sheffield, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.